Clinical studies of Asciminib

Asciminib (Asciminib) is the first STAMP of BCR::ABL1 (specifically targetingABL myristoyl pocket) inhibitor, inApproved by the U.S. Food and Drug Administration (FDA) in October 2021 for the treatment of CP-CML patients who are resistant or intolerant to two previous TKI therapies and patients with T315I mutations.

In a phase 1 trial, aximinib was evaluated in CML as a third or higher line of treatment for patients with CML-CP or CML-AP, or as a second or higher line of treatment for patients with T315I mutations. A subsequent phase 3 trial showed that aximinib was more effective than bosutinib in patients with CP-CML who had failed two or more previous TKIs, regardless of the number of previous TKI treatments. Ongoing studies are evaluating the potential use of aceminib in a variety of settings, including newly diagnosed CML, CML that has responded poorly to or is resistant to prior TKIs targeting deep molecular response (DMR), achieving first or second treatment-free remission (TFR), and Philadelphia chromosome-positive acute lymphoblastic leukemia.

The original drug of Asiminib has not yet been launched in China, so it cannot be included in medical insurance. The original drug of Asiminib currently sold overseas is very expensive. Generic drugs of Asiminil are also produced and marketed overseas, and their drug ingredients are basically the same as those of the original drug. For example, the price of 40mg*60 tablets produced by a Laos pharmaceutical factory may be more than 4,000 yuan per box (the price may fluctuate due to exchange rate effects), and the price is relatively cheap. For more drug information and specific prices, please consult Yaode’s medical consultant.